This study is designed to test standard treatment for blood clots with standard treatments and a new treatment. All participants will receive blood-thinning drugs, the standard treatment for blood clots. In addition half of the study participants will be randomly chosen to have their clot dissolved using a clot-busting drug (TPA) that a doctor will inject directly into the clotted vein through a specially designed drug delivery catheter.

Participants are followed for 2 years to assess possible symptoms related to the clot and how well both treatments prevent complications.

• Blood clots in a leg vein
• Age 16-79
• Other eligibility criteria may apply. Please contact study coordinator

• Symptom duration more than 14 days for the current Deep Vein Thrombosis (DVT) episode (i.e. subacute or chronic DVT).
• Other exclusion criteria may apply. Please contact study coordinator.

Truman Cantrell RN Truman.Cantrell@providence.org

509-474-4319